Intranasal fentanyl for pain control: current status with a focus on patient considerations

Eric Prommer, Lisa Thompson, Eric Prommer, Lisa Thompson

Abstract

Of several newer delivery systems under development and investigation for the administration of opioids, the intranasal route has received a substantial amount of attention. Intranasal administration is a convenient form of delivery that is applicable to several opioids. It has the potential for self-administration, combined with a rapid onset of action, allowing for patient-controlled analgesia. In clinical practice, intranasal administration has been found to be a reliable drug delivery method that is familiar to patients. Intranasal opioids have proven to be useful in both in-hospital and out-of-hospital pain management settings. Fentanyl, a highly lipophilic step 3 opioid, has been evaluated for intranasal administration. The purpose of this review is to examine the role of the nasal route of opioid administration and examine the evidence base for the use of fentanyl intranasally.

Keywords: breakthrough pain; fentanyl; intranasal; pain.

Figures

Figure 1
Figure 1
Fentanyl structure.

References

    1. Patt RB, Burton AW. Evaluation and Treatment of Chronic Pain. New York: Lippincott, Williams & Wilkins; 1998. Pain associated with advanced malignancy, including adjuvant analgesic drugs in cancer pain management; pp. 337–376.
    1. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372–380.
    1. Dosen-Micovic L, Ivanovic M, Micovic V. Steric interactions and the activity of fentanyl analogs at the [mu]-opioid receptor. Bioorg Med Chem. 2006;14:2887–2895.
    1. Shelley K, Paech MJ. The clinical applications of intranasal opioids. Curr Drug Deliv. 2008;5:55.
    1. Vyas TK, Shahiwala A, Marathe S, Misra A. Intranasal drug delivery for brain targeting. Curr Drug Deliv. 2005;2:165–175.
    1. Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand. 2002;46:759–770.
    1. Birkhoff M, Leitz M, Marx D. Advantages of intranasal vaccination and considerations on device selection. Indian J Pharm Sci. 2009;71:729.
    1. Veldhorst-Janssen NML, Fiddelers AAA, van der Kuy PHM, et al. A review of the clinical pharmacokinetics of opioids, benzodiazepines, and antimigraine drugs delivered intranasally. Clin Ther. 2009;31:2954–2987.
    1. Schwagmeier R, Oelmann T, Dannappel T, Striebel HW. Patientenakzeptanz gegennber der patientenkontrollierten intranasalen Analgesie (PCINA) Der Anaesthesist. 1996;45:231–234.
    1. Pennington AK, Ratcliffe JH, Wilson CG, Hardy JG. The influence of solution viscosity on nasal spray deposition and clearance. Int J Pharm. 1988;43:221–224.
    1. Illum L, Jorgensen H, Bisgaard H, et al. Bioadhesive microspheres as a potential nasal drug delivery system. Int J Pharm. 1987;39:189–199.
    1. Veldhorst-Janssen NML, Fiddelers AAA, van der Kuy PHM, et al. Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: a prospective, randomized, double-blind, placebo-controlled study. Clin Ther. 2010;32:1427–1436.
    1. Paech MJ, Lim CB, Banks SL, et al. A new formulation of nasal fentanyl spray for postoperative analgesia: a pilot study. Anaesthesia. 2003;58:740–744.
    1. Grape S, Schug SA, Lauer S, Schug BS. Formulations of fentanyl for the management of pain. Drugs. 2010;70:57–72.
    1. Panagiotou I, Mystakidou K. Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications. Expert Rev Anticancer Ther. 2010;10:1009–1021.
    1. Christrup LL, Foster D, Popper LD, et al. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther. 2008;30:469–481.
    1. Fisher A, Watling M, Smith A, Knight A. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int J Clin Pharmacol Ther. 2010;48:138.
    1. Prommer E. The role of fentanyl in cancer-related pain. J Palliat Med. 2009;12:947–954.
    1. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273–281.
    1. Coluzzi PH, Schwartzberg L. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR) Pain. 2001;91:123–130.
    1. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22:805.
    1. Kress HG, Oronska A, Kaczmarek Z, et al. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 [mu] g for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther. 2009;31:1177–1191.
    1. Taylor D, Galan V, Weinstein SM, et al. Fentanyl pectin nasal spray in breakthrough cancer pain. J Support Oncol. 2010;8:184.
    1. Portenoy RK, Raffaeli W, Torres LM, et al. Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients. J Opioid Manag. 2010;6:319.
    1. Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin. 2009;25:2805–2815.
    1. Striebel HW, Olmann T, Spies C, Brummer G. Patient-controlled intranasal analgesia (PCINA) for the management of postoperative pain: a pilot study. J Clin Anesth. 1996;8:4–8.
    1. Toussaint S, Maidl J, Schwagmeier R, Striebel HW. Patient-controlled intranasal analgesia: effective alternative to intravenous PCA for postoperative pain relief. Can J Anaesth. 2000;47:299–302.
    1. Christrup LL, Foster D, Popper LD, et al. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther. 2008;30:469–481.
    1. Cheng X, Li JH. Effects of fentanyl administrated nasally and intravenously in post-operative analgesia in pediatric children: a comparative study of 36 cases. Zhonghua Yi Xue Za Zhi. 2008;88:2898.
    1. Galinkin JL, Fazi LM, Cuy RM, et al. Use of intranasal fentanyl in children undergoing myringotomy and tube placement during halothane and sevoflurane anesthesia. Anesthesiology. 2000;93:1378.
    1. Finkel JC, Cohen IT, Hannallah RS, et al. The effect of intranasal fentanyl on the emergence characteristics after sevoflurane anesthesia in children undergoing surgery for bilateral myringotomy tube placement. Anaesth Analg. 2001;92:1164.
    1. Voronov P, Tobin MJ, Billings K, et al. Postoperative pain relief in infants undergoing myringotomy and tube placement: comparison of a novel regional anesthetic block to intranasal fentanylûa pilot analysis. Pediatric Anesthesia. 2008;18:1196–1201.
    1. Borland M, Jacobs I, King B, O’Brien D. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Ann Emerg Med. 2007;49:335–340.
    1. Borland ML, Bergesio R, Pascoe EM, et al. Intranasal fentanyl is an equivalent analgesic to oral morphine in paediatric burns patients for dressing changes: a randomised double blind crossover study. Burns. 2005;31:831–837.
    1. Zeppetella G, O’Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000;20:87–92.
    1. Sitte T, Bausewein C. Intranasal fentanyl for episodic breathlessness. J Pain Symptom Manage. 2008;36:e3.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa